Navigation Links
BioMarin to Present at the William Blair Growth Stock Conference
Date:6/3/2009

NOVATO, Calif., June 3 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the William Blair Growth Stock Conference in Chicago on Wednesday, June 10, 2009 at 12:00 p.m. CT.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase I clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

    Contacts:

    Investors                                    Media
    Eugenia Shen                                 Susan Berg
    BioMarin Pharmaceutical Inc.                 BioMarin Pharmaceutical Inc.
    (415) 506-6570                               (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
2. BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
5. BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET)
6. BioMarin to Present at the Cowen and Company 28th Annual Healthcare Conference
7. BioMarin to Present at the Lehman Brothers Global Healthcare Conference
8. BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
9. BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
10. BioMarin to Present at the 27th Annual J.P. Morgan Healthcare Conference
11. BioMarin Supports Observance of Rare Disease Day February 28
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... Tanya Atagi, MD, is excited to announce ... Atagi Plastic Surgery and Skin Aesthetics. , To tighten skin on the face, ... ultrasound energy. Smoother, younger-looking skin is revealed on all other areas of the body ...
(Date:8/17/2017)... CO (PRWEB) , ... August 17, 2017 , ... ... Moral Injury: The Journey to Healing Through Forgiveness ($15.99, paperback, 9781498497626; $7.99, ... (war) trauma, to encourage inner healing of memories and achieve forgiveness, through a ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Pot Valet is ... service growing to every city in the state, and soon, every state in the ... their need to visit a cannabis dispensary altogether. , According to Pot ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Centrifugation is more ... in the laboratory that we can no longer do without. And just like a ... of your device. , In this webinar, attendees will learn about the most important ...
(Date:8/17/2017)... Seattle, WA and Lighthouse Point, FL (PRWEB) , ... ... ... Seattle-based healthcare technology firm and Cancer Center Business Development Group, a Florida-based oncology ... that examined patient care data to quantify the dollar amount of attributable savings ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... LOVELAND, Colo. , July 26, 2017 ... Tristan Guttridge and the Bimini SharkLab to custom design the ... diagnostic images of sharks in their native habitat. In ... for Discovery Channel,s Shark Week, Dr. Guttridge approached ... to take pregnancy diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 /PRNewswire/ ... drugs to treat rare nervous system diseases, has concluded a ... and market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before ... promising results in a Phase 2 study conducted in ... in the United States ...
Breaking Medicine Technology: